Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Displaced Palestinian families suffer as heavy rains flood Gaza tent camps - 2At least 11 killed in South Africa mass shooting
- 3Christopher Nolan's 'The Odyssey' trailer: See Anne Hathaway, Matt Damon and Tom Holland in 1st look at movie
- 4The most effective method to Beat Dental Tension and Guarantee Customary Exams
- 5Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- FDA approves Wegovy pill for weight loss
- Most loved Public Dish: Which One Addresses Its Nation Best?
- What really happens when 140 reality stars come face to face with their biggest fans
- Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
- The most effective method to Pick the Ideal Lab Precious stone Wedding band
- Should you get an RSV vaccine this fall? What to know and where to get a shot
- Sean Penn lights up, Kylie Jenner gets A-list approval and 7 other moments you didn’t see at the Golden Globes
